Biotech News
These news items are provided from various selected news sites and filtered through our keywords.
- Merck KGaA Signs $550 Million Cancer Pact With Threshold Pharmaceuticals, Inc.
- DARMSTADT, Germany, Feb 03, 2012 (BUSINESS WIRE) -- --Deal provides Threshold with an upfront payment of EUR 19 million ($25 million), plus further potential milestones and royalties as well as an option to co-commercialize in the United States
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc...
- Idenix Pharmaceuticals, Inc. Receives FDA Notification That Partial Clinical Hold on IDX184 Removed
- CAMBRIDGE, Mass., Feb. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on IDX184 has been removed...
- Q&A About $100 Million Asia, Emerging Markets Strategy With AstraZeneca PLC's Head of R&D
- The health challenges of China and Asia offer big opportunities for multinational pharma companies. Cases of chronic diseases, such as diabetes, are on the rise in the region, as are lung, gastric, and liver cancers. China alone is likely to be the worlds third-largest pharmaceutical market by this year, with sales of more than $50 billion. AstraZeneca, the largest multinational pharmaceutical company...
- Merrimack Pharmaceuticals Inc. Scraps IPO Plans
- Boston Business Journal by Julie M. Donnelly, Reporter
Merrimack Pharmaceuticals has postponed its $166 million IPO, originally scheduled for this week, according to IPO tracker Renaissance Capital, due to poor market conditions.
The Cambridge, Mass-based company, which is developing potential treatments for cancer, planned to sell 16,666,667 shares of common stock at an estimated...
- Discovery Laboratories Gets FDA OK for Aerosol Medicines Delivery System
- WARRINGTON, Pa., Feb. 2, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced AFECTAIR is now registered with the Food and Drug Administration (FDA) and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient...
- Athersys, Inc. Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease
- CLEVELAND, Feb. 1, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX - News) today announced positive results from its Phase I clinical trial of MultiStem(R), its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants (HSCT) for the treatment of leukemia and related conditions. According to the Center for International Blood and Marrow Transplant...
- Drugmakers Including GlaxoSmithKline Scuttle Plan for Approval System Pushed by Biotechs
- Drugmakers including GlaxoSmithKline Plc have fought off a U.S. senators proposal that would have approved medicines for diseases that are fatal, or have no existing treatments, based on fewer human trials. The plan, drafted by Democratic Senator Kay Hagan of North Carolina, was being pushed by biotechnology companies to speed up approvals and make the process less expensive. It would have created...
- Ligand Pharmaceuticals Inc. Presents Full Data from Successful Phase II Trial of Captisol-Enabled??, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings
- SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood...
- Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd.'s Bowel Dysfunction Drug Succeeds in Second Phase III Study
- BETHESDA, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Patients received lubiprostone...
- Valeant Pharmaceuticals International Acquires in Brazil for $85 Million
- MISSISSAUGA, Ontario, Feb. 1, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has acquired Probiotica Laboratorios Ltda., a leader in sports nutrition and food supplements in Brazil. Probiotica currently markets a full line of over-the-counter sports nutrition products and other food supplements, with a 30 percent share...
- Sangamo BioSciences, Inc. to Partner With Shire plc for $13 Million to Develop DNA Technology
- DUBLIN and RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in genome-editing technology, announced today that they have entered into a collaboration and license agreement to develop therapeutics for...
- Female Frontrunners in Biotech
- Excelling in industry is not easy, especially if youre a woman. According to a 2010 study of New England biotech firms, females comprised only about 12 percent of biotech founders, despite earning about half of the biological science PhDs. And women are equally underrepresented at the senior management level, holding just 12 percent of senior executive positions in the worlds top drug companies and...
- Impax Pharmaceuticals Gains Rights for US Sales of AstraZeneca PLC's Zomig; Paying $130 Million in 2012
- HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Pharmaceuticals, the branded products business unit of Impax Laboratories, Inc. (NASDAQ: IPXL - News), announced today that it has licensed from AstraZeneca the exclusive United States (U.S.) commercial rights to Zomig (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations. As part of a Distribution, License, Development and Supply...
- FDA Approves Boehringer Ingelheim Corporation, Eli Lilly and Company's Diabetics Therapy Jentadueto???
- RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ --Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new...
- FDA Approves Vertex Pharmaceuticals Incorporated's Cystic Fibrosis Drug
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease. KALYDECO (kuh-LYE-deh-koh) is approved for people with CF ages 6 and older who have at least one copy of the G55...
- Savient Pharmaceuticals, Inc. Appoints Interim Chief Executive Officer
- EAST BRUNSWICK, N.J., Feb. 1, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company's Board of Directors has appointed David Y. Norton, a member of the Savient Board and former Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, to the role of Interim Chief Executive...
- Ablynx Receives Another EUR $5 Million Milestone as Boehringer Ingelheim Corporation Selects Nanobody Candidate for Pre-Clinical Development
- SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--MEDIAN Technologies (Paris:ALMDT)(ALMDT), a leading services provider for image interpretation and management in oncology clinical trials, and software provider for medical imaging, announced today the signature of a landmark contract with the top pharmaceutical company SANOFI for the interpretation and end-to-end management of medical images in a phase II...
- Transparency Life Sciences, LLC Launched as World's First Drug Development Company Based on Open Innovation
- New York, NY and Philadelphia, PA - January 31, 2012 - Transparency Life Sciences, LLC (TLS) the worlds first drug development company based on open innovation, announced its official launch today with the introduction of a prototype of the companys crowdsourced web platform that allows patients, physicians, researchers and other stakeholders to contribute to the design of clinical studies. The...
- BioSante Pharmaceuticals, Inc. Cuts 25% of Workforce
- LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced a corporate update.
Corporate development: In light of the recently announced top-line results from BioSantes two pivotal Phase III LibiGel (testosterone gel) efficacy trials, BioSante is evaluating its corporate strategy. BioSante continues to investigate alternative strategies to utilize...
- Orexo AB, Janssen Pharmaceutical K.K. Axe Preclinical-Stage Deal in Respiratory Diseases
- UPPSALA, Sweden--(BUSINESS WIRE)-- Regulatory News: Orexo AB (STO:ORX.ST - News) and Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV ("Janssen"), have decided to end their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs and a third, undisclosed Janssen program. Each party has regained all commercial...
- Tech Council of Maryland Appoints as Interim CEO
ROCKVILLE, MD--(Marketwire - January 30, 2012) - The Tech Council of Maryland (TCM), Maryland's largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today announced that Art...
- Teva Pharmaceutical Industries Limited's Cephalon, Inc. Recalls Treanda Leukemia Drug Due to Glass Fragments
- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) US subsidiary Cephalon has recalled a lot of its Treanda leukemia drug, because glass fragments were found in one of the vials. The US Food and Drug Administration (FDA) said in a statement that Cephalon distributed the Treanda lot TB30111 to wholesalers and distributors between March 22 and October 5, 2011, and notified those recipients...
- GlaxoSmithKline, Eli Lilly and Company, Pfizer Inc. Said to be Interested in Turkey's
- GlaxoSmithKline Plc (GSK), Eli Lilly & Co. and Pfizer Inc. (PFE) are among about half a dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, three people with knowledge of the situation said. The owners of Mustafa Nevzat, or MN Pharmaceuticals as the Istanbul-based company is known, have hired Bank of America Merrill...
- FDA Approves Amylin Pharmaceuticals, Inc. and Alkermes plc's BYDUREON??? -- The First and Only Once-Weekly Treatment for Type 2 Diabetes
- SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON (exenatide extended-release for injectable suspension) the first once-weekly treatment for type 2 diabetes. BYDUREON...
- Teva Pharmaceutical Industries Limited Eyes $2 Billion Micro Laboratories, Inc. Acquisition
- The fact that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has explicitly said that it has no plans to make large acquisitions any time soon has not stopped speculations about the company's next buyout. Indian website "VCCircle" reports that Teva is a contender to acquire Micro Labs Ltd. for almost $2 billion. While the amount is not on the scale of Teva's last three multibillion...
- Drugmakers Including GlaxoSmithKline and Sanofi (France) Join $785 Million Tropical-Disease Fight
- LONDON, Jan. 30, 2012 /PRNewswire-USNewswire/ -- Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.
Uniting efforts with NTD...
- Bayer AG Gets Approval for Gadovist For Children Aged 2-6 Years
- German pharmaceutical company Bayer AG (BAYN.XE) said Friday it got approval for use of Gadovist 1.0 in children aged two to six years in the Europe Union. Gadovist is a contrast medium, which is injected to make diseases visible in magnetic resonance tomography examinations, an imaging technique. It is approved for the most frequently conducted contrast enhanced magnetic resonance tomography examinations...
- Valeant Pharmaceuticals International Withdraws Bid for ISTA Pharmaceuticals, Inc.
- MISSISSAUGA, Ontario, Jan. 30, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has withdrawn its offer to acquire ISTA Pharmaceuticals Inc. (Nasdaq: ISTA) for $7.50 per share in cash. Valeant had previously announced that the offer would only remain open until
- Lannett Company, Inc. Receives FDA Approval for Hydrochlorothiazide Capsules, 12.5 mg
- PHILADELPHIA--(BUSINESS WIRE)-- Lannett Company, Inc. (NYSE AMEX: LCI) today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrochlorothiazide Capsules, 12.5 mg. Hydrochlorothiazide Capsules, 12.5 mg, is therapeutically equivalent to the reference listed drug, MicrozideCapsules, 12.5 mg, of Watson Pharmaceuticals...
- Antitrust: Commission Closes Procedural Case Against Servier
- (NewDesignWorld Press Center) - Brussels - The Commission has closed an investigation into Les Laboratoires Servier for suspected provision of misleading and incorrect information to the Commission's pharmaceuticals sector inquiry.
In 2010, the Commission addressed statements of objections to Les Laboratoires Servier and Servier SAS, a French pharmaceutical company, taking the provisional...
- Infinity Pharmaceuticals Inc. Halts Phase II Cancer Drug Trial
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced interim data from its double-blind, randomized, placebo-controlled Phase 2 study comparing saridegib (also known as IPI-926) in combination with gemcitabine to placebo plus gemcitabine in 122 patients with previously untreated, metastatic pancreatic cancer. The primary endpoint of the Phase 2 study is overall...
- The Hotbed Driving Force in Biotech: Massachusetts
By Michelle Wong, BioSpace.com
Massachusetts is picking up steam in the biotech industry while...- Pfizer Inc. Sued by Employees Over Retirement Plans
- Employees of Pfizer Inc. have filed suit against the company, alleging the world's largest drug maker failed to properly manage its retirement plans and caused losses totaling hundreds of millions over the past decade in one of the hubs of the pharmaceutical industry. The suit, filed Wednesday in federal court in Puerto Rico, alleges Pfizer allowed employees to amass such high concentrations of company...
- Verastem, Inc. Bucks the Trend, Raises $55 Million in IPO
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold...
